Stroke

Victoza Approved to Reduce Risk of MACE

The Food and Drug Administration (FDA) approval was based on data from the randomized, double-blind, placebo-controlled LEADER trial (n=9,340) that evaluated long-term effects of Victoza vs. placebo in patients with type 2 diabetes with high risk of major cardiovascular events (MACE).